Laurie Sehn, MD of British Columbia Cancer Agency, Vancouver, Canada discusses the heterogeneity of diffuse large B-cell lymphoma (DLBCL). According to Dr Sehn, it is important to stop looking at DLBCL as one entity. A lot of ongoing trials are trying to recognize the heterogeneity of DLBCL and to tailor therapy based on biology. She mentions the PHOENIX trial (NCT01855750), which enrolled a group of patients with the non-germinal center B-cell subtype (GCB) subtype of DLBCL and asked whether adding ibrutinib to R-CHOP would be an advantage. Recorded at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.